Bod Australia reports strong sales growth in H2 2020 by Martin Lane January 8, 2021January 8, 2021 Bod Australia has announced strong sales growth in the second half of 2020, filling 3,941 prescriptions […]
Industry reacts to TGA down-scheduling decision with cautious optimism by Martin Lane December 17, 2020December 17, 2020
ASX-listed cannabis companies look to finance their next stages of growth by Martin Lane December 14, 2020December 14, 2020
Bod Australia sees 106% increase in monthly MediCabilis prescriptions by Emma Castle November 18, 2020November 18, 2020
Bod Australia furthers European expansion, with plans for US market underway by Martin Lane October 20, 2020October 20, 2020
Brexit looms but the UK remains a top target for Australian cannabis companies by Rachel Williamson October 1, 2020October 1, 2020
Bod achieves ‘Generally Recognised as Safe’ status in the US by Emma Castle September 23, 2020September 24, 2020
Your daily dose of cannabis news: the US$130billion industry; Bod’s share price surge; CannPal’s breakthrough; Elixinol Global’s HFA update; Cannasouth does Colorado deal; Aphria and Aurora merger off by Martin Lane July 22, 2020August 5, 2020
Warning over CBD ‘red herring’ amid concerns about TGA demands by Steve Jones July 15, 2020August 5, 2020
